[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Medical News & Perspectives
January 21, 2009

Researchers Worry About Myopathy Risk for Patients Taking High-Dose Simvastatin

JAMA. 2009;301(3):261-262. doi:10.1001/jama.2008.939

New Orleans—Statin therapy using 80 mg of simvastatin daily may be on its last legs, some physicians suggest, because the drug is associated with increased risk of myopathy. In addition, when compared with the drug's efficacy at lower doses, high-dose simvastatin is minimally or no more effective in reducing low-density lipoprotein cholesterol (LDL-C) or decreasing risk of major vascular events.

The negative appraisal of high-dose simvastatin was prompted by new results from the Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH), presented at the Scientific Sessions of the American Heart Association held here in November.